{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-236039","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.460250+00:00","generated_at":"2026-05-30T16:46:37.546399+00:00","sec_items":["1.01","5.02","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inhibikase raises ~$110M in private placement; appoints four new directors","bullets":["Gross proceeds ~$110M from common stock, pre-funded warrants, and Series A-1/B-1 warrants at $1.37 per share unit.","Company to seek stockholder approval to increase authorized shares; meeting within 90 days of close of offering.","Board expands from 5 to 7; appoints Bellini, Munshi, Kush, Canner effective Oct 21.","Series A-1 warrants ($1.37) expire 30 days after Phase 2b safety readout; Series B-1 ($1.49) after efficacy readout.","New directors invest alongside: BSquared $2M, Munshi family $500K, Kush trust $200K, Soleus Capital ~$21.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-236039","json":"https://secwatch.observer/filing/0001193125-24-236039.json","markdown":"https://secwatch.observer/filing/0001193125-24-236039.md","text":"https://secwatch.observer/filing/0001193125-24-236039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/d882121d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:46:37.546399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38934d4f49","claim":"David Canner was appointed as Class II Director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Amit Munshi and David Canner to serve as Class II directors of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"3ffbd9ecde","claim":"Roberto Bellini was appointed as Class I Director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"the Board will appoint Roberto Bellini to serve as a Class I director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"6372d59755","claim":"Amit Munshi was appointed as Class II Director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Amit Munshi and David Canner to serve as Class II directors of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"7cd5aaf141","claim":"Arvind Kush was appointed as Class III Director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Arvind Kush to serve as a Class III director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"cc5ec390b1","claim":"Roberto Bellini was elected as Chairperson of the Board at Inhibikase Therapeutics, Inc..","evidence_excerpt":"It is expected that the Board will elect Mr. Bellini as Chairperson of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}